Research Advances on Circumventing Tumor Multidrug Resistance
文献类型:期刊论文
作者 | Maio Zehong; Ding Jian![]() |
刊名 | Chinese Journal of Cancer
![]() |
出版日期 | 2003 |
卷号 | 22期号:8页码:886-892 |
关键词 | Multidrug resistance (MDR) Antitumor agents P-glycoprotein (P-gp) Ceramide |
ISSN号 | 1000-467X |
其他题名 | 抗肿瘤多药耐的研究进展 |
文献子类 | Review |
英文摘要 | Tumor multidrug-resistant(MDR) reverters inhibit the function of drug transporters and thus reverse MDR. In contrast, anti-MDR agents circumvent tumor MDR by directly inhibiting or killing MDR tumor. In recent years, the development of novel anti-MDR agents has become a major focus of research. This review summarized the advances in MDR mechanisms concentrating on the relationships between P-glycoprotein and apoptotic regulation and between ceramide signal system and MDR. With this understanding, the authors classified anti-MDR agents for the first time as agents which are structurally modified from MDR-related drugs, disrupt MDR mechanisms, induce caspase-independent apoptosis, interfere with ceramide metabolism, and are mechanism-unknown, Meanwhile, their mechanisms and major features of actions were also discussed. |
WOS研究方向 | Oncology (provided by Clarivate Analytics) |
语种 | 中文 |
CSCD记录号 | CSCD:1247268 |
源URL | [http://119.78.100.183/handle/2S10ELR8/268464] ![]() |
专题 | 药理学第一研究室 |
作者单位 | Division of Anti-tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Shanghai Institute of Materia Medica, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 201203, China. |
推荐引用方式 GB/T 7714 | Maio Zehong,Ding Jian. Research Advances on Circumventing Tumor Multidrug Resistance[J]. Chinese Journal of Cancer,2003,22(8):886-892. |
APA | Maio Zehong,&Ding Jian.(2003).Research Advances on Circumventing Tumor Multidrug Resistance.Chinese Journal of Cancer,22(8),886-892. |
MLA | Maio Zehong,et al."Research Advances on Circumventing Tumor Multidrug Resistance".Chinese Journal of Cancer 22.8(2003):886-892. |
入库方式: OAI收割
来源:上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。